Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MajesTEC-3: teclistamab + daratumumab versus daratumumab-based triplets in relapsed or refractory multiple myeloma
jRCT2031210635Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of teclistamab, daratumumab, pomalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression Free Survival. Started Jul 2022; status: active, not recruiting.
02
Drugs
teclistamabdaratumumabpomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031210635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210635.